Rohto Faces Activist Shareholder Proposals Ahead of June Shareholders’ Meeting

Rohto Pharmaceutical Co ( (JP:4527) ) just unveiled an update.

Rohto Pharmaceutical Co., Ltd. disclosed that it has received two shareholder proposals ahead of its 90th Ordinary General Meeting of Shareholders scheduled for June 24, 2026. The proposals were submitted by AVI Japan Opportunity Trust PLC and LONGCHAMP SICA V, both significant shareholders seeking changes in governance and capital policy.

The first proposal calls for the dismissal of one director, signaling investor pressure on current board composition and oversight. The second, more extensive proposal seeks amendments to the Articles of Incorporation to establish a Strategic Review Committee, alter the body deciding dividends, authorize share repurchases, approve compensation for a restricted stock plan, change the mix of outside directors, embed cost-of-capital and share price awareness in management, and revise the record date for the annual meeting, underscoring an activist push for stronger shareholder alignment. The board plans to announce its views on these proposals after deliberation, setting up a potentially pivotal vote on corporate governance and capital allocation at the upcoming meeting.

The most recent analyst rating on (JP:4527) stock is a Buy with a Yen2980.00 price target. To see the full list of analyst forecasts on Rohto Pharmaceutical Co stock, see the JP:4527 Stock Forecast page.

More about Rohto Pharmaceutical Co

Rohto Pharmaceutical Co., Ltd., listed on the TSE Prime, operates in the pharmaceutical and healthcare industry, producing over-the-counter medicines, skincare, and related consumer health products. The company targets both domestic and international markets, positioning itself as a key player in Japan’s consumer healthcare and eye care segments.

Average Trading Volume: 786,833

Technical Sentiment Signal: Sell

Current Market Cap: Yen554.5B

Find detailed analytics on 4527 stock on TipRanks’ Stock Analysis page.